# Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors

> **NCT01313065** · PHASE1 · COMPLETED · sponsor: **Vaccinex Inc.** · enrollment: 42 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** VX15/2503

## Key facts

- **NCT ID:** NCT01313065
- **Lead sponsor:** Vaccinex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313065, "Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01313065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*